Latest On Agios Pharmaceuticals, Inc (AGIO):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-24 13:19 EST | News | Agios Pharmaceuticals: Good Execution, A Good Deal Of Cash, Some Hurdles | N/A |  |
| 2023-05-04 22:01 EST | News | Agios Pharmaceuticals, Inc. 2023 Q1 - Results - Earnings Call Presentation | N/A | |
| 2023-05-04 22:01 EST | News | Agios Pharmaceuticals, Inc. (AGIO) Q1 2023 Earnings Call Transcript | N/A | |
| 2023-05-04 09:00 EST | News | Agios Pharmaceuticals GAAP EPS of -$1.47 beats by $0.23, revenue of $5.6M beats by $0.37M | N/A | |
| 2023-05-03 20:46 EST | News | Agios Pharmaceuticals Q1 2023 Earnings Preview | N/A | |
About Agios Pharmaceuticals, Inc (AGIO):
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA (enasidenib), an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which has completed Phase II clinical trials to treat IC eligible frontline AML; that is in Phase III clinical trials for treating IC ineligible frontline AML; and that is in Phase III clinical trials for the treatment of cholangiocarcinoma, as well as in read more... early stage clinical development to treat glioma and solid tumors. In addition, the company is developing IDHIFA, which has completed Phase II clinical study for treating IC eligible frontline AML; and that is in Phase I/II clinical trials for the treatment of IC ineligible frontline AML. Further, it is developing mitapivat, which is in Phase III clinical trials to treat pyruvate kinase deficiency, as well as in Phase II clinical study for treating thalassemia and sickle cell disease; vorasidenib (AG-881) that is in Phase I clinical trials for the treatment of solid tumors, including glioma; AG-270, which is in Phase I dose-escalation trial to treat methylthioadenosine phosphorylase deleted tumors; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is based in Cambridge, Massachusetts.
General
- Name Agios Pharmaceuticals, Inc
- Symbol AGIO
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 562
- Fiscal Year EndDecember
- IPO Date2013-07-24
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.agios.com
Valuation
- Forward PE 8.1
- Price/Sales (Trailing 12 Mt.) 17.51
- Price/Book (Most Recent Quarter) 8.98
- Enterprise Value Revenue 15.36
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$6.07
- Next Year EPS Estimate -$6.10
- Next Quarter EPS Estimate -$1.29
- Profit Margin -161%
- Operating Margin -156%
- Return on Assets -23%
- Return on Equity -63%
- Revenue 203.2 million
- Earnings Per Share -$6.67
- Revenue Per Share $2.95
- Gross Profit -167079000
- Quarterly Earnings Growth 24.3%
Highlights
- Market Capitalization 3.38 billion
- EBITDA -399112000
- PE Ratio 1.63
- Analyst Target Price $64.89
- Book Value Per Share $5.77
Share Statistics
- Shares Outstanding 69.36 million
- Shares Float 61.75 million
- % Held by Insiders 1133%
- % Held by Institutions 92.34%
- Shares Short 5.82 million
- Shares Short Prior Month 5.68 million
- Short Ratio 8.4
- Short % of Float 11%
- Short % of Shares Outstanding 8%
Technicals
- Beta 1.62
- 52 Week High $58.93
- 52 Week Low $32.47
- 50 Day Moving Average 50.87
- 200 Day Moving Average 42.95
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Agios Pharmaceuticals, Inc (AGIO) Dividend Calendar:
Agios Pharmaceuticals, Inc (AGIO) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Agios Pharmaceuticals, Inc (AGIO) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Agios Pharmaceuticals, Inc (AGIO) Chart:
Agios Pharmaceuticals, Inc (AGIO) News:
Below you will find a list of latest news for Agios Pharmaceuticals, Inc (AGIO) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Agios Pharmaceuticals, Inc (AGIO) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest AGIO Trades:
Agios Pharmaceuticals, Inc (AGIO) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-05 | 8-K (Current report) | |
| 2020-11-05 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-10-19 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-21 | 8-K (Current report) | |
| 2020-09-08 | 8-K (Current report) | |
| 2020-09-04 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-10 | SC 13G/A (Statement of acquisition of beneficial ownership by individuals) | |
| 2020-07-30 | 8-K (Current report) | |
| 2020-07-30 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-06-12 | 8-K (Current report) | |
| 2020-06-12 | 8-K (Current report) | |
| 2020-06-01 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-01 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-01 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-01 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-01 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-01 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-01 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-05-29 | 8-K (Current report) | |
| 2020-05-29 | 8-K (Current report) | |
Agios Pharmaceuticals, Inc (AGIO) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Agios Pharmaceuticals, Inc (AGIO). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 1133%
Institutional Ownership: 9234%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-09-02 | Carman Alenson | Principal Accounting Officer | Sell | 250.00 | 39.93 | 9,982.50 | 184.00 | |
| 2020-05-29 | JOHN MARAGANORE | Director | Buy | 1,878.00 | 30,172.00 | | ||
| 2020-05-29 | IAN T CLARK | Director | Buy | 1,878.00 | 3,278.00 | | ||
| 2020-05-29 | Maykin Ho | Director | Buy | 1,878.00 | 3,278.00 | | ||
| 2020-05-29 | Paul J Clancy | Director | Buy | 1,878.00 | 3,278.00 | | ||
| 2020-05-29 | David Scadden | Director | Buy | 1,878.00 | 3,849.00 | | ||
| 2020-05-29 | Kaye I Foster-Cheek | Director | Buy | 1,878.00 | 5,478.00 | | ||
| 2020-05-20 | Christopher Bowden | Chief Medical Officer | Buy | 3,583.00 | 35.16 | 125,978.28 | 11,889.00 | |
| 2020-05-20 | Christopher Bowden | Chief Medical Officer | Sell | 3,583.00 | 50.01 | 179,200.16 | 8,306.00 | |
| 2020-04-22 | Andrew Hirsch | Chief Financial Officer | Buy | 5,893.00 | 26,199.00 | | ||
| 2020-04-13 | Christopher Bowden | Chief Medical Officer | Buy | 5,280.00 | 10,598.00 | | ||
| 2020-04-13 | Andrew Hirsch | Chief Financial Officer | Buy | 5,387.00 | 21,905.00 | | ||
| 2020-04-13 | JACQUALYN A FOUSE | Chief Executive Officer | Buy | 12,379.00 | 54,101.00 | | ||
| 2020-04-13 | Bruce Car | Chief Scientific Officer | Buy | 6,874.00 | 6,874.00 | | ||
| 2020-04-13 | Jonathan Biller | Chief Legal Officer | Buy | 8,523.00 | 8,523.00 | | ||
| 2020-03-02 | Carman Alenson | Principal Accounting Officer | Sell | 345.00 | 47.30 | 16,318.50 | 184.00 | |
| 2020-02-26 | Carman Alenson | Principal Accounting Officer | Sell | 472.00 | 47.12 | 22,240.64 | 184.00 | |
| 2020-02-22 | David P Schenkein | Director | Buy | 2,775.00 | 105,933.00 | | ||
| 2020-02-22 | Andrew Hirsch | Chief Financial Officer | Buy | 3,333.00 | 17,574.00 | | ||
| 2020-02-22 | Christopher Bowden | Chief Medical Officer | Buy | 3,333.00 | 6,914.00 | |